David Maloney

Dave Maloney received his BS from the University of Vermont and subsequently his PhD from the University of Virginia in the laboratory of Dr. Sidney Hecht. Following a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center with Dr. Samuel Danishefsky, he joined the NIH in 2007 as a medicinal chemistry group leader at the National Center for Advancing Translational Sciences (NCATS). During this time, Dr. Maloney led a team of senior scientists in lead-identification and lead optimisation efforts. He managed a project portfolio encompassing a broad range of therapeutic areas and target classes which involved close collaboration and interaction with leading researchers from around the world in both academia and the private sector. During his research career he has co-authored over 100 scientific manuscripts and is co-inventor on more than 10 patents. In 2017 he left the NIH to pursue his passion of entrepreneurship and co-founded Veralox Therapeutics were he currently serves as the CSO.